Detalhe da pesquisa
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38048786
2.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36724453
3.
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Br J Haematol
; 204(4): 1243-1248, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38083865
4.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37311468
5.
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis.
Blood
; 140(12): 1408-1418, 2022 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35667047
6.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood
; 140(21): 2228-2247, 2022 11 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36130297
7.
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Haematologica
; 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38299605
8.
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Ann Hematol
; 103(1): 117-123, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38030891
9.
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Ann Hematol
; 103(6): 1941-1945, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38634915
10.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31914241
11.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36635381
12.
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
Am J Hematol
; 98(12): E360-E363, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37705256
13.
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
Cancer
; 128(19): 3495-3501, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35942592
14.
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
Cancer
; 128(21): 3880-3887, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36107670
15.
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Br J Haematol
; 198(4): 713-720, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35751140
16.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood
; 136(24): 2812-2823, 2020 12 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32730593
17.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood
; 136(2): 157-170, 2020 07 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32347921
18.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36153475
19.
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Ann Hematol
; 101(1): 139-146, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34622316
20.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35510486